What keeps driving our innate passion is our global ambition.

About 2000+ of our 9000-plus employees are based in international markets. One element binding us all is a common vision and belief in our abilities to create change, to synergise our creative thinking and technologies for a healthier world. Today, Wockhardt’s presence in both the leading and emerging markets of the world is a testimony to the success of its globalisation strategy.

Wockhardt’s commitment to international quality standards in all its business processes has propelled it to the ranks of the leading pharmaceutical and biotechnology companies operating out of India, with a market capitalisation of over $ 1 billion and a strong global footprint. Today, over 70% of Wockhardt’s turnover comes from the international markets, most of it from Europe and the US.

The Company has built a strong presence in healthcare encompassing pharmaceutical formulations, bulk actives, biopharmaceuticals, vaccines and nutritional products. Wockhardt was recently adjudged as a ‘Business Superbrand’ by a UK-based organisation tracking reputed consumer and corporate brands in 45 countries including US, France, Germany, Australia and Canada. The Superbrands are selected by a council of independent experts in recognition of emotional and tangible benefits to stakeholders. Wockhardt is the only pharmaceutical company from India to get this tribute.

Besides formulations, the Company is also amongst the world's leading manufacturers of active pharmaceutical ingredients (APIs). Wockhardt is among the world’s top three suppliers of Dextromethorphan, Vitamin B12 and Captopril.

The Company’s brand equity has made it the preferred partner for many international pharmaceutical companies. Today, we have strong relationships with well-known companies such as Amylin and Eli Lilly of US, Bristol of UK, and Eisai and Daiichi of Japan.